About PathCision Medicine
PathCision Medicine is a Healthcare company based in Watertown (United States) founded in 2022 by David Lee and Shana Wang. Targeted therapies for metastatic cancer treatment are developed. PathCision Medicine has raised $1.9 million across 2 funding rounds. Its chief executive, as recorded, is Shana Wang. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its competitors include Moderna, BeiGene and Incyte; 2 of its 3 listed competitors have raised funding.
Company details
PathCision Medicine was founded in 2022 and is based in Watertown, United States. Operations focus on the biotechnology sector, where targeted therapies for metastatic cancer are developed. Tissue pathology insights are utilized to create a biologic modality enabling metastasis-selective delivery for various indications. The approach addresses unmet needs in oncology through precise therapeutic mechanisms.
- Headquarters Watertown, United States
- Founders David Lee, Shana Wang
- SectorsHealthcare
- Website pathcisionmedicine.com
- Social LinkedIn X
- Total Equity Funding$1.9M (USD)
in 2 rounds
- Latest Funding Round$200K (USD), Seed
Feb 2024
Funding Insights of PathCision Medicine
PathCision Medicine has successfully raised a total of $1.9M across 2 strategic funding rounds. The most recent funding activity was a Seed round of $200 thousand completed in February 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $1.9M
- Total Rounds 2
- Last Round Seed — $200,000
- First Round $1.7M
(Nov 2022)
All 2 funding rounds of PathCision Medicine with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2024 | $200,000 | Seed | – | – | – |
| Nov 2022 | $1.7M | Seed | – | – | – |
People of PathCision Medicine
2 people are tracked at PathCision Medicine (2 in leadership).
| Name | Role | Group |
|---|---|---|
David Lee | Co-Founder | Leadership |
Shana Wang | Co-Founder & CEO | Leadership |
Complete people profiles for PathCision Medicine
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of PathCision Medicine
3 dated milestones of PathCision Medicine across 2 years, from founding to its latest funding, stage changes and deals.
- Founded PathCision Medicine is founded.
- Funding First funding round of $1.7M.
- Funding Latest funding round, Seed, of $200K.
Competitors of PathCision Medicine
PathCision Medicine has 3 listed competitors in our database, 2 of them funded. They include Moderna, BeiGene and Incyte.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| incyte.com | 1991 | Wilmington, United States | 1,387 | Small molecules are developed for cancer and skin disease treatments. |
Detailed competitors of PathCision Medicine
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of PathCision Medicine
The website of PathCision Medicine (pathcisionmedicine.com) receives about 1.3K visits a month.
- Monthly visits1.3K
▲ 282.1% vs previous month
Top companies in Oncology
3 companies that operate in the same segment as PathCision Medicine (Oncology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about PathCision Medicine
PathCision Medicine was founded in 2022.
PathCision Medicine is headquartered in Watertown, United States.
Shana Wang is the CEO of PathCision Medicine, as recorded in our data. They have also founded this company.
PathCision Medicine is a funded company, having raised a total of $1.9M across 2 funding rounds to date. The company's 1st funding round was a Seed of $1.7M, raised on Nov 2022.
PathCision Medicine was founded in 2022 and is based in Watertown, United States. Operations focus on the biotechnology sector, where targeted therapies for metastatic cancer are developed. Tissue pathology insights are utilized to create a biologic modality enabling metastasis-selective delivery for various indications. The approach addresses unmet needs in oncology through precise therapeutic mechanisms.